Skip to main content

Table 3 Differences in quality of life trajectories between amyloid-positive patients with SCD, MCI, and dementia

From: A longitudinal study on quality of life along the spectrum of Alzheimer’s disease

  EQ-5D utilities VAS
Unadjusted Model 1 Model 2 Unadjusted Model 1 Model 2
Β (SE) Β (SE) Β (SE) Β (SE) Β (SE) Β (SE)
SCD 0.02 (0.02) 0.02 (0.02) 0.001 (0.02) 6.52 (2.15)* 6.45 (2.15)* 4.20 (2.31)
MCI 0.04 (0.02) 0.03 (0.02) 0.02 (0.02) 3.38 (1.93) 3.21 (1.94) 1.51 (2.05)
Dementia Ref Ref Ref Ref Ref Ref
Time * SCD 0.02 (0.005)* 0.02 (0.005)* 0.03 (0.005)* 0.94 (0.54)** 0.95 (0.54)** 0.97 (0.54)**
Time * MCI 0.02 (0.005)* 0.02 (0.005)* 0.02 (0.005)* 1.13 (0.51)* 1.14 (0.51)* 1.14 (0.51)*
Time * dementia Ref Ref Ref Ref Ref Ref
  1. Model 1: adjusted for age, squared age (EQ-5D only), and sex
  2. Model 2: additionally adjusted for comorbidity score, education, and EQ-5D scale (EQ-5D only)
  3. *p < 0.05
  4. **p < 0.10 for interaction term
  5. Of note: main effect of syndrome diagnosis groups represents the average difference between SCD vs. dementia and MCI vs. dementia at baseline; interaction effect represents the difference in QoL over time between SCD vs. dementia and MCI vs. dementia
  6. SCD subjective cognitive decline, MCI mild cognitive impairment, Aβ positive amyloid positive, SE standard error